前列腺素E_1联合阿托伐他汀对老年高血压肾病患者相关指标的影响

Effect of Prostaglandin E_1 Combined with Atorvastatin on Related Indicators in Elderly Patients with Hypertensive Nephropathy

目的:探讨前列腺素E_1联合阿托伐他汀对老年高血压肾病患者相关指标的影响。方法:70例老年高血压肾病患者随机均分为对照组和观察组。对照组患者均给予阿托伐他汀钙片10 mg,口服,每日1次;观察组患者在对照组治疗的基础上给予前列腺素E_1注射液10μg加入0.9%氯化钠注射液250 ml中,静脉滴注,每日1次。两组患者疗程均为2周。两组患者治疗期间均给予优质低蛋白、低盐和低胆固醇饮食,并予降压、降脂等常规治疗。观察两组患者治疗前后心率(HR)、收缩压(SBP)、舒张压(DBP)、三酰甘油(TG)、总胆固醇(TC)、高密度脂蛋白胆固醇(HDL-C)、低密度脂蛋白胆固醇(LDL-C)、血肌酐(Scr)、24 h尿蛋白定量(TP/24h)、尿微量白蛋白(mAlb)、尿β_2微球蛋白(β_2-MG)、尿素氮(BUN)及不良反应发生情况。结果:治疗后,两组患者HR、SBP、DBP、TG、TC、LDL-C均显著低于同组治疗前,差异均有统计学意义(P<0.05),但上述各指标两组间及HDL-C治疗前后比较,差异均无统计学意义(P>0.05);Scr、TP/24 h、mA1b、β_2-MG、BUN均显著低于同组治疗前,且观察组低于对照组,差异均有统计学意义(P<0.05)。两组患者不良反应发生率比较,差异无统计学意义(P>0.05)。结论:在常规治疗基础上,前列腺素E_1联合阿托伐他汀与单用阿托伐他汀均可显著改善老年高血压肾病患者心率、血压和血脂水平,但在保护肾功能方面前列腺素E_1联合阿托伐他汀优于单用阿托伐他汀,且安全性相当。

OBJECTIVE：To investigate the effect of prostaglandin E1 combined with atorvastatin on related indicators in elderly patients with hypertensive nephropathy. METHODS： 70 elderly patients with hypertensive nephropathy were randomly divided into control group and observation group. Control group was orally given 10 mg Atorvastatin calcium tablet, once a day; observation group was additionally given 10μg Prostaglandin E1 injection, adding into 250 ml 0.9% Sodium chloride injection by intravenous infusion, once a day. The treatment course for both groups was 2 weeks. All patients were given quality low-protein, low-salt and low cholesterol diet, depressurization, lipid-lowering and other conventional treatment. Heart rate （HR）, systolic blood pressure （SBP）, diastolic blood pressure （DBP）, triglyceride （TG）, total cholesterol （TC）, high-density lipoprotein cholesterol（HDL-C）, low-density lipoprotein cholesterol （LDL-C）, serum creatinine（Scr）, 24h urinary protein （TP/24 h）, microalbuminuria （mAlb）, urinary β2-microglobulin （ β2-MG）, blood urea nitrogen （BUN） before and after treatment, and incidence of adverse reactions in 2 groups were observed. RESULTS： After treatment, HR, SBP, DBP, TG, TC and LDL-C in 2 groups were significantly lower than before, and difference was statistically significant（P〈0.05）, but there was no significant difference in the above-mentioned indicators between 2 groups and HDL-C before and after treatment（P〉0.05） ; Scr, TP/24 h, mAlb, β2-MG and BUN were significantly lower than before, and observation group was lower than control group, the differences were statistically significant （P〈 0.05）. And there was no significant difference in the incidence of adverse reactions（P〉0.05）. CONCLUSIONS： Based on the conventional treatment, prostaglandin E1 combined with atorvastatin can effectively improve the HR, blood pressure and blood lipid of elderly patients with hypertensive nephropathy; however, prostaglandin E1 combined with atorvastatin is better than atorvastatin alone in aspect of protecting renal function, with similar safety.